- BioStem Technologies (OTC: BSEM) to present at Centri Capital Conference on April 22, 2025.
- CEO Jason Matuszewski to highlight the proprietary BioREtain® technology.
- Company's products are processed at an FDA registered and AATB accredited facility.
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company, is set to showcase its innovative placental-derived products for advanced wound care at the Centri Capital Conference. The event will be held at the Nasdaq headquarters in New York City on April 22, 2025. The company's CEO, Jason Matuszewski, is scheduled to present at 10:30 AM ET, focusing on their proprietary BioREtain® processing method.
The BioREtain® method is a cutting-edge technology developed to maintain growth factors and preserve tissue structure vital for advanced wound care. BioStem's product portfolio, which includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®, will be highlighted during the presentation. These products are processed at the company's FDA registered and AATB accredited facility located in Pompano Beach, Florida, ensuring compliance with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP).
Attendees at the Centri Capital Conference will also have the opportunity to engage in one-on-one meetings with Mr. Matuszewski to explore potential collaborations and investment opportunities. For those unable to attend in person, the presentation will be webcast, providing broader access to BioStem’s latest developments and innovations.
Investors and interested parties can stay updated with BioStem Technologies' progress by subscribing to their email distribution list or following them on Twitter and LinkedIn for real-time updates.
